Description
Fc Engineered Anti-Human CD11a Antibody, CDC-Enhanced (BioBet-C056ZP) is a recombinant monoclonal Whole Humanized antibody against CD11a. This product is a CDC enhanced antibody produced by our proprietary platform.
Indication
Psoriasis
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop CDC-enhanced rituximab. For commercial partners interested in our CDC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD11A
Full Name
CD11A
Background
ITGAL encodes the integrin alpha L chain. Integrins are heterodimeric integral membrane proteins composed of an alpha chain and a beta chain. This I-domain containing alpha integrin combines with the beta 2 chain (ITGB2) to form the integrin lymphocyte function-associated antigen-1 (LFA-1), which is expressed on all leukocytes. LFA-1 plays a central role in leukocyte intercellular adhesion through interactions with its ligands, ICAMs 1-3 (intercellular adhesion molecules 1 through 3), and also functions in lymphocyte costimulatory signaling. Involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes and monocytes. Contributes to natural killer cell cytotoxicity.
Gene ID
3683
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
Humanized IgG1
Indication
Moderate to Severe Chronic Plaque Psoriasis
Moderate to Severe Chronic Plaque Psoriasis
